Novo Nordisk announced it will discontinue its cell therapy R&D activities and lay off nearly all 250 employees in that division as part of a larger corporate reorganization led by CEO Maziar Mike Doustdar. The move ends development across several modalities including programs targeting Parkinson’s disease, chronic heart failure and a Type 1 diabetes cell‑therapy effort. Novo said it will seek partners with manufacturing scale to continue development of select innovations, while redirecting resources toward prioritized areas such as obesity and diabetes. The decision follows Novo’s broader cost‑savings plan and comes amid a flurry of recent industry exits from cell‑therapy investments by other large pharmas.